Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
35.96 ^USD	+1.78%		+2.98%	+25.38%

Apr. 12	Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating	MT
Apr. 12	Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating	MT

Revolution Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 26, 2024 at 04:08 pm EST

Revolution Medicines, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 11.58 million compared to USD 35.38 million a year ago. Net loss was USD 436.37 million compared to USD 248.71 million a year ago.

Basic loss per share from continuing operations was USD 3.86 compared to USD 3.08 a year ago. Diluted loss per share from continuing operations was USD 3.86 compared to USD 3.08 a year ago.

Latest news about Revolution Medicines, Inc.

Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating	Apr. 12	MT
Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating	Apr. 12	MT
North American Morning Briefing : Stock Futures -2-	Apr. 11	DJ
Aethon Therapeutics, Inc. Announces Collaboration with Revolution Medicines, Inc. to Discover and Develop Novel Aethon Antibody Programs	Apr. 04	CI
Revolution Medicines Insider Sold Shares Worth $805,652, According to a Recent SEC Filing	Mar. 13	MT
Piper Sandler Starts Revolution Medicines With Overweight Rating, $43 Price Target	Mar. 11	MT
HC Wainwright Raises Revolution Medicines Price Target to $44 From $28, Maintains Buy Rating	Mar. 08	MT
Revolution Medicines Files Mixed-Securities Shelf	Mar. 05	MT
Wedbush Adjusts Revolution Medicines' Price Target to $42 From $41, Keeps Outperform Rating	Feb. 27	MT
Revolution Medicines Q4 Net Loss Widens, Revenue Drops	Feb. 26	MT
Transcript : Revolution Medicines, Inc., Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
Revolution Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (RVMD) REVOLUTION MEDICINES Posts Q4 Revenue $742,000, vs. Street Est of $1.2M	Feb. 26	MT
Revolution Medicines, Inc. Provides Earnings Guidance for Full Year 2024	Feb. 26	CI
Revolution Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Transcript : Revolution Medicines, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 11:15 AM	Jan. 09
North American Morning Briefing : Boeing Drags -2-	Jan. 08	DJ
Revolution Medicines Insider Sold Shares Worth $387,884, According to a Recent SEC Filing	Jan. 04	MT
Wedbush Starts Revolution Medicines With Outperform Rating, $41 Price Target	Jan. 04	MT
Revolution Medicines Insider Sold Shares Worth $966,996, According to a Recent SEC Filing	Dec. 29	MT
UBS Initiates Coverage on Revolution Medicines With Buy Rating, $40 Price Target	Dec. 20	MT
Revolution Medicines Insider Sold Shares Worth $125,000, According to a Recent SEC Filing	Dec. 08	MT
Raymond James Starts Revolution Medicines With Outperform Rating, Price Target is $30	Nov. 16	MT
Revolution Medicines Closes Acquisition of EQRx in All-Stock Deal	Nov. 09	MT
Revolution Medicines, Inc. Appoints Sandra J. Horning, M.D., as Member of the Board	Nov. 09	CI

Chart Revolution Medicines, Inc.

Duration

Period

More charts

Company Profile

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Revolution Medicines, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.96 USD

Average target price

41.62 USD

Spread / Average Target

+15.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REVOLUTION MEDICINES, INC.	+25.38%	6.13B
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research